[
  {
    "ts": null,
    "headline": "Top Analyst Reports for Oracle, IBM & Merck",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) and Merck & Co., Inc. (MRK), as well as a micro-cap stock Earth Science Tech, Inc. (ETST).",
    "url": "https://finnhub.io/api/news?id=882b4e053434270817ebf1b7ce91068db1d9e80b811b01a1230462102be9f907",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747262640,
      "headline": "Top Analyst Reports for Oracle, IBM & Merck",
      "id": 134460809,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) and Merck & Co., Inc. (MRK), as well as a micro-cap stock Earth Science Tech, Inc. (ETST).",
      "url": "https://finnhub.io/api/news?id=882b4e053434270817ebf1b7ce91068db1d9e80b811b01a1230462102be9f907"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)",
    "summary": "RAHWAY, N.J., May 14, 2025--WELIREG PPGL FDA Approval News Release",
    "url": "https://finnhub.io/api/news?id=c949838b4aafb9b52eceeda4714a0fb24c44995a6c1dcc5db765bea8689d22a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747257300,
      "headline": "FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)",
      "id": 134460889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., May 14, 2025--WELIREG PPGL FDA Approval News Release",
      "url": "https://finnhub.io/api/news?id=c949838b4aafb9b52eceeda4714a0fb24c44995a6c1dcc5db765bea8689d22a4"
    }
  },
  {
    "ts": null,
    "headline": "Citigroup Downgrades Merck (MRK)",
    "summary": "Citigroup Downgrades Merck (MRK)",
    "url": "https://finnhub.io/api/news?id=8be137337f7b94387da33fc029998c7da9c4560379d871258623025166c3a6a4",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747250977,
      "headline": "Citigroup Downgrades Merck (MRK)",
      "id": 134450214,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8be137337f7b94387da33fc029998c7da9c4560379d871258623025166c3a6a4"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors",
    "summary": "The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL, rare neuroendocrine tumors that can spread to other parts of the body. Welireg received approval from the FDA and European Medicines Agency for adult patients with advanc",
    "url": "https://finnhub.io/api/news?id=2428ceae88b5464f12448cb937cf9819e3c104ac96672d2f63e75e7a79c8bd6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747250265,
      "headline": "FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors",
      "id": 134460890,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL, rare neuroendocrine tumors that can spread to other parts of the body. Welireg received approval from the FDA and European Medicines Agency for adult patients with advanc",
      "url": "https://finnhub.io/api/news?id=2428ceae88b5464f12448cb937cf9819e3c104ac96672d2f63e75e7a79c8bd6c"
    }
  },
  {
    "ts": null,
    "headline": "Merck Gets FDA Approval for Tumor Treatment Welireg",
    "summary": "Merck Gets FDA Approval for Tumor Treatment Welireg",
    "url": "https://finnhub.io/api/news?id=52b760069c66bd2a4752dc203715f40ed78b6a13d7b937d04dc6c6e5492987b5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747245300,
      "headline": "Merck Gets FDA Approval for Tumor Treatment Welireg",
      "id": 134469811,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck Gets FDA Approval for Tumor Treatment Welireg",
      "url": "https://finnhub.io/api/news?id=52b760069c66bd2a4752dc203715f40ed78b6a13d7b937d04dc6c6e5492987b5"
    }
  },
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) Showcases Broad Cancer Research Portfolio At ASCO Annual Meeting",
    "summary": "Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint. However, the company experienced a 3% decline in its share price last week, during a period when broader market indices, led by tech gains, posted positive returns. Despite this decline, Merck's ongoing initiatives in cancer treatment and digital health technologies signal sustained efforts against...",
    "url": "https://finnhub.io/api/news?id=433c08efd674f2974a0481552fc64e82f7b1d80cb01dbd86e630caafc6214dba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747244192,
      "headline": "Merck (NYSE:MRK) Showcases Broad Cancer Research Portfolio At ASCO Annual Meeting",
      "id": 134460892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint. However, the company experienced a 3% decline in its share price last week, during a period when broader market indices, led by tech gains, posted positive returns. Despite this decline, Merck's ongoing initiatives in cancer treatment and digital health technologies signal sustained efforts against...",
      "url": "https://finnhub.io/api/news?id=433c08efd674f2974a0481552fc64e82f7b1d80cb01dbd86e630caafc6214dba"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Health Care Roundup: Market Talk",
    "url": "https://finnhub.io/api/news?id=f6dd3ef56639b299e8fb12c035814b8d8414ac248e0daae08e242bd4c089eb3a",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747244160,
      "headline": "Health Care Roundup: Market Talk",
      "id": 134469783,
      "image": "",
      "related": "MRK",
      "source": "DowJones",
      "summary": "Health Care Roundup: Market Talk",
      "url": "https://finnhub.io/api/news?id=f6dd3ef56639b299e8fb12c035814b8d8414ac248e0daae08e242bd4c089eb3a"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Merck'S WELIREG® (Belzutifan) For The Treatment Of Adults And Pediatric Patients 12 Years And Older With Locally Advanced, Unresectable, Or Metastatic Pheochromocytoma Or Paraganglioma (PPGL)",
    "summary": "Merck & Co Inc: * FDA APPROVES MERCK’S WELIREG® FOR THETREATMENT OFADULTS AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH LOCALLYADVANCED, UNRESECTABLE, OR METASTATIC...",
    "url": "https://finnhub.io/api/news?id=da2c3229144d4fdd4698afee4b057492b9e389e4f042d57a4abc1f1e98a284fe",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747243054,
      "headline": "FDA Approves Merck'S WELIREG® (Belzutifan) For The Treatment Of Adults And Pediatric Patients 12 Years And Older With Locally Advanced, Unresectable, Or Metastatic Pheochromocytoma Or Paraganglioma (PPGL)",
      "id": 134454988,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: * FDA APPROVES MERCK’S WELIREG® FOR THETREATMENT OFADULTS AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH LOCALLYADVANCED, UNRESECTABLE, OR METASTATIC...",
      "url": "https://finnhub.io/api/news?id=da2c3229144d4fdd4698afee4b057492b9e389e4f042d57a4abc1f1e98a284fe"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript)",
    "summary": "Merck &amp; Co., Inc. (NYSE:MRK) BofA Securities 2025 Healthcare Conference May 14, 2025 1:40 PM ETCompany ParticipantsJannie Oosthuizen - PresidentPeter...",
    "url": "https://finnhub.io/api/news?id=e5ec0f7ec0c02f3059d5dcc28283cceef65d9ab3cf202ab7242913b8809143c4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747241426,
      "headline": "Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript)",
      "id": 134454945,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck &amp; Co., Inc. (NYSE:MRK) BofA Securities 2025 Healthcare Conference May 14, 2025 1:40 PM ETCompany ParticipantsJannie Oosthuizen - PresidentPeter...",
      "url": "https://finnhub.io/api/news?id=e5ec0f7ec0c02f3059d5dcc28283cceef65d9ab3cf202ab7242913b8809143c4"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
    "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747237080,
      "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
      "id": 134453013,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54"
    }
  },
  {
    "ts": null,
    "headline": "Exelixis: A Notable Quarter",
    "summary": "Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the latest EXEL stock analysis here.",
    "url": "https://finnhub.io/api/news?id=48e27fdd0e0396402ad3dcb5a6d060e383ae5ef947114413be8fc5307738c247",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747234414,
      "headline": "Exelixis: A Notable Quarter",
      "id": 134448421,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473708731/image_1473708731.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the latest EXEL stock analysis here.",
      "url": "https://finnhub.io/api/news?id=48e27fdd0e0396402ad3dcb5a6d060e383ae5ef947114413be8fc5307738c247"
    }
  },
  {
    "ts": null,
    "headline": "US FDA expands use of Merck's cancer drug for adrenal gland tumors",
    "summary": "The U.S. Food and Drug Administrationsaid on Wednesday it has approved the expanded use of Merck'scancer drug to treat two types adrenal gland tumors. The drug, Welireg, became the...",
    "url": "https://finnhub.io/api/news?id=e58cf587a56e87d8a271935f79ecc8e83d97cc0d187b2406dca73b2c625fac00",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747227077,
      "headline": "US FDA expands use of Merck's cancer drug for adrenal gland tumors",
      "id": 134440008,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administrationsaid on Wednesday it has approved the expanded use of Merck'scancer drug to treat two types adrenal gland tumors. The drug, Welireg, became the...",
      "url": "https://finnhub.io/api/news?id=e58cf587a56e87d8a271935f79ecc8e83d97cc0d187b2406dca73b2c625fac00"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Belzutifan For Pheochromocytoma Or Paraganglioma",
    "summary": "FDA: * FDA APPROVES BELZUTIFAN FOR PHEOCHROMOCYTOMA ORPARAGANGLIOMAFurther company coverage: ...",
    "url": "https://finnhub.io/api/news?id=19e1887da74a2048e05b7c8af6ceb6ac48908f86bc8cc5b344652e4abdae048f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747225754,
      "headline": "FDA Approves Belzutifan For Pheochromocytoma Or Paraganglioma",
      "id": 134438516,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "FDA: * FDA APPROVES BELZUTIFAN FOR PHEOCHROMOCYTOMA ORPARAGANGLIOMAFurther company coverage: ...",
      "url": "https://finnhub.io/api/news?id=19e1887da74a2048e05b7c8af6ceb6ac48908f86bc8cc5b344652e4abdae048f"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
    "summary": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
    "url": "https://finnhub.io/api/news?id=fe994dfedeced3bae800e6590a04318330ed9fec1d3b55e456f1986dc367eb7e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747220700,
      "headline": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
      "id": 134437978,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
      "url": "https://finnhub.io/api/news?id=fe994dfedeced3bae800e6590a04318330ed9fec1d3b55e456f1986dc367eb7e"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
    "summary": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
    "url": "https://finnhub.io/api/news?id=8ab9dcccbd821b4af88441cd016dbca2988656c853d954eedc4541b773e0ce23",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747218240,
      "headline": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
      "id": 134437591,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
      "url": "https://finnhub.io/api/news?id=8ab9dcccbd821b4af88441cd016dbca2988656c853d954eedc4541b773e0ce23"
    }
  },
  {
    "ts": null,
    "headline": "FDA upheaval pushes some biotech firms to plan early trials out of US",
    "summary": "Some U.S. biotech companiesare considering moving early-stage trials of new medicinesoutside the United States as worry grows that layoffs and policychanges at the drugs watchdog under the Trump...",
    "url": "https://finnhub.io/api/news?id=140c972816daf9ae558849326400a7e67752a9443e727c0b5fec0d27648852dc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747195272,
      "headline": "FDA upheaval pushes some biotech firms to plan early trials out of US",
      "id": 134433034,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Some U.S. biotech companiesare considering moving early-stage trials of new medicinesoutside the United States as worry grows that layoffs and policychanges at the drugs watchdog under the Trump...",
      "url": "https://finnhub.io/api/news?id=140c972816daf9ae558849326400a7e67752a9443e727c0b5fec0d27648852dc"
    }
  }
]